Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients

被引：0
|
作者：
Shaohua Zhang
Lei Li
Tao Wang
Li Bian
Haixu Hu
Chunhong Xu
Bing Liu
Yi Liu
Massimo Cristofanilli
Zefei Jiang
机构：
[1] Affiliated Hospital of Academy of Military Medical Sciences,Department of Breast Cancer
[2] Affiliated Hospital of Academy of Military Medical Sciences,Translational Medicine Center, Laboratory of Oncology
[3] Jefferson University Hospital,Department of Medical Oncology
来源：
BMC Cancer | / 16卷
关键词：
Circulating Tumor Cells (CTCs); Human Epidermal Growth Factor Receptor 2 (HER2); Metastatic Breast Cancer (MBC); Anti-HER2 therapy; Real-time HER2 status;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Response to anti-HER2 neoadjuvant chemotherapy in HER2-positive invasive breast cancers with different HER2 FISH patterns
    Lv, Hong
    Bai, Qian-Ming
    Li, Ming
    Cai, Meng-Yuan
    Zhou, Shu-Ling
    Liu, Yin
    Wang, Zhong-Hua
    Shui, Ruo-Hong
    Lu, Hong-Fen
    Xu, Xiao-Li
    Yu, Bao-Hua
    Tu, Xiao-Yu
    Bi, Rui
    Cheng, Yu-Fan
    Zhou, Xiao-Yan
    Shao, Zhi-Min
    Yang, Wen-Tao
    JOURNAL OF CLINICAL PATHOLOGY, 2024,
  • [22] Prospective characterization of HER2-positive circulating tumor cells in patients with HER2-negative metastatic breast cancer
    Krop, Ian E.
    Macrae, Erin
    Galler, Sarah R.
    Bischoff, Farideh
    Fauni, Romeo
    Sales, Edgar
    Huynh, Lan
    Mitchell, Christine
    Clarin-Tamayo, Trisky
    Anderson, Mark
    Abad, Leslie
    Winer, Eric
    CANCER RESEARCH, 2015, 75
  • [23] Anti-HER2 treatment in advanced metastatic HER2-negative breast cancer patients with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells.
    Kurbacher, Christian M.
    Eichler, Christian A.
    Quade, Annegret Barbara
    Kunstmann, Gerhard
    Herz, Susanne
    Kurbacher, Jutta Anna
    Warm, Mathias R.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [24] Peripheral blood monocyte count prediction for anti-HER2 combination therapy: Outcomes in HER2-positive metastatic breast cancer patients.
    Radwi, Amer Naeem
    Albeladi, Reyadh Khalid
    Alzahrani, Shahrazad Abdulsalam
    Alahmadi, Raghad Abdulrahman
    Aljohani, Haneen Abdulrahman
    Ahmed, Dalia Ismaiel
    CANCER RESEARCH, 2021, 81 (13)
  • [25] Pathologic complete response to neoadjuvant anti-HER2 therapy is associated with HER2 immunohistochemistry score in HER2-positive early breast cancer
    Chen, Hai-Long
    Chen, Qiang
    Deng, Yong-Chuan
    MEDICINE, 2021, 100 (44)
  • [26] Anti-HER2 Drugs for the Treatment of Advanced HER2 Positive Breast Cancer
    Stanowicka-Grada, Malwina
    Senkus, Elzbieta
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2023, 24 (11) : 1633 - 1650
  • [27] HER2-Positive Circulating Tumor Cells in Breast Cancer
    Ignatiadis, Michail
    Rothe, Francoise
    Chaboteaux, Carole
    Durbecq, Virginie
    Rouas, Ghizlane
    Criscitiello, Carmen
    Metallo, Jessica
    Kheddoumi, Naima
    Singhal, Sandeep K.
    Michiels, Stefan
    Veys, Isabelle
    Rossari, Jose
    Larsimont, Denis
    Carly, Birgit
    Pestrin, Marta
    Bessi, Silvia
    Buxant, Frederic
    Liebens, Fabienne
    Piccart, Martine
    Sotiriou, Christos
    PLOS ONE, 2011, 6 (01):
  • [28] Differential responses of HER2-positive breast cancer cells to anti-HER2 treatment.
    Yu, Rong
    Chiu, Kung Y.
    Shi, Lili
    Zhang, Peter
    Duan, Chun-Xiao
    Lu, Sunny
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] The incidence and outcomes of brain metastases in HER2-positive metastatic breast cancer with the advent of modern anti-HER2 therapies
    Shachar, S. Strulov
    Deal, A. M.
    Vaz-Luis, I.
    Dees, E. C.
    Carey, L. A.
    Hassett, M. J.
    Garrett, A. L.
    Benbow, J. M.
    Hughes, M. E.
    Mounsey, L.
    Lin, N.
    Anders, C. K.
    CANCER RESEARCH, 2017, 77
  • [30] Anti-HER2 neoadjuvant and adjuvant therapies in HER2 positive breast cancer
    Guarneri, V.
    Barbieri, E.
    Dieci, M. V.
    Piacentini, F.
    Conte, P.
    CANCER TREATMENT REVIEWS, 2010, 36 : S62 - S66
12345